Subtype
Human Papillomavirus-Independent Cervical Adenocarcinoma
CI-CAN-00005527Explore in graph →
2 active trials
- NCIt
- C180848
Loading cancer entity…
Subtype
CI-CAN-00005527Explore in graph →
Clinical trials
3 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05046080 | Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix | recruiting | — | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT06730347 |
| A Study of Lorigerlimab in Participants With Advanced Solid Tumors |
| recruiting |
| Phase 2 |
| 80 |
| MacroGenicsINDUSTRY |
| 3 |
| Jun 2, 2026 |
| clinicaltrials |
Data updated 22 days agoSource updated Aug 10, 2026source: clinicaltrials